Evidence map›Paper›PMID 26010368›Full record

Trial reportPloS one2015

Longitudinal study of informed consent in innovative therapy research: experience and provisional recommendations from a multicenter trial of intracerebral grafting.

Laurent Cleret de Langavant, Sophie Sudraud, Christophe Verny, Pierre Krystkowiak, Clémence Simonin, Philippe Damier, Jean-François Demonet, Frédéric Supiot, Amandine Rialland, David Schmitz and 3 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Laurent Cleret de LangavantAP-HP, Hôpital Henri Mondor, Centre de Référence-Maladie de Huntington, Neurologie cognitive, Créteil, France; Université Paris Est, Faculté de médecine, Créteil, France; INSERM U955, Equipe 01, Neuropsychologie Interventionnelle, Créteil, France; Département d'Etudes Cognitives, Ecole Normale Supérieure, PSL Research University, Paris, France.
Sophie SudraudAP-HP, Hôpital Henri Mondor, Centre de Référence-Maladie de Huntington, Neurologie cognitive, Créteil, France; Université Paris Est, Faculté de médecine, Créteil, France; INSERM U955, Equipe 01, Neuropsychologie Interventionnelle, Créteil, France.
Christophe VernyCHU d'Angers, Centre de Référence des Maladies Neurogénétiques, service de neurologie, Angers, France; UMR CNRS 6214 INSERM U1083, CHU d'Angers, Angers, France.
Pierre KrystkowiakCHU d'Amiens, service de neurologie, Amiens, France; EA 4559, Laboratoire de Neurosciences Fonctionnelles et Pathologies, Université de Picardie Jules Verne, Amiens, France.
Clémence SimoninUniversité Lille Nord de France, Lille, France; INSERM UMR837, Institut de Recherches sur le Cancer de Lille (IRCL), Lille, France; CHRU Lille, Département de Neurologie et des Mouvements Anormaux, Lille, France.
Philippe DamierCHU Nantes, Service de Neurologie, Nantes, France; UFR Médecine, Université de Nantes, Nantes, France.
Jean-François DemonetLeenaards Memory Centre, Clinical Neuroscience Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland; INSERM U825, Université de Toulouse, Toulouse, France.
Frédéric SupiotCliniques Universitaires de Bruxelles Hôpital Erasme, Bruxelles, Belgique.
Amandine RiallandAP-HP, Hôpital Henri Mondor, Unité de Recherche Clinique, Creteil, France.
David SchmitzAP-HP, Hôpital Henri Mondor, Unité de Recherche Clinique, Creteil, France.
Patrick MaisonAP-HP, Hôpital Henri Mondor, Unité de Recherche Clinique, Creteil, France.
Katia YoussovAP-HP, Hôpital Henri Mondor, Centre de Référence-Maladie de Huntington, Neurologie cognitive, Créteil, France; Université Paris Est, Faculté de médecine, Créteil, France; INSERM U955, Equipe 01, Neuropsychologie Interventionnelle, Créteil, France; Département d'Etudes Cognitives, Ecole Normale Supérieure, PSL Research University, Paris, France.
Anne-Catherine Bachoud-LéviAP-HP, Hôpital Henri Mondor, Centre de Référence-Maladie de Huntington, Neurologie cognitive, Créteil, France; Université Paris Est, Faculté de médecine, Créteil, France; INSERM U955, Equipe 01, Neuropsychologie Interventionnelle, Créteil, France; Département d'Etudes Cognitives, Ecole Normale Supérieure, PSL Research University, Paris, France.
Assistance Publique – Hôpitaux de Paris · FRInserm · FRCentre Hospitalier Universitaire Amiens-Picardie · FRHôpitaux Universitaires Henri-Mondor · FRNantes Université · FRUniversité d'Angers · FRUniversité Libre de Bruxelles · BEUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is an urgent need to assess and improve the consent process in clinical trials of innovative therapies for neurodegenerative disorders.

methodsWe performed a longitudinal study of the consent of Huntington's disease patients during the Multicenter Fetal Cell Intracerebral Grafting Trial in Huntington's Disease (MIG-HD) in France and Belgium. Patients and their proxies completed a consent questionnaire at inclusion, before signing the consent form and after one year of follow-up, before randomization and transplantation. The questionnaire explored understanding of the protocol, satisfaction with the information delivered, reasons for participating in the trial and expectations regarding the transplant. Forty-six Huntington's disease patients and 27 proxies completed the questionnaire at inclusion, and 27 Huntington's disease patients and 16 proxies one year later.

resultsThe comprehension score was high and similar for Huntington's disease patients and proxies at inclusion (72.6% vs 77.8%; P > 0.1) but only decreased in HD patients after one year. The information satisfaction score was high (73.5% vs 66.5%; P > 0.1) and correlated with understanding in both patients and proxies. The motivation and expectation profiles were similar in patients and proxies and remained unchanged after one year.

conclusionsCognitively impaired patients with Huntington's disease were capable of consenting to participation in this trial. This consent procedure has presumably strengthened their understanding and should be proposed before signing the consent form in future gene or cell therapy trials for neurodegenerative disorders. Because of the potential cognitive decline, proxies should be designated as provisional surrogate decision-makers, even in competent patients.

Indexed as

Informed ConsentStem Cell TransplantationSurveys and QuestionnairesAdultAllograftsBelgiumFemaleFollow-Up StudiesFranceHumansHuntington DiseaseMaleMiddle AgedNeural Stem Cells

Identifiers

PMID26010368
PMCPMC4444138
OpenAlexW1587999021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.